A Phase II Study Evaluating Andamertinib in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR PACC or EGFR L861Q Mutations.

by | Jan 13, 2026 | Clinical Trials | 0 comments

​ Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: PLB1004

Sponsors: Avistone Biotechnology Co., Ltd.

Not yet recruiting Conditions: Non-Small-Cell Lung Cancer
Interventions: Drug: PLB1004
Sponsors: Avistone Biotechnology Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *